29 February 2024.
|
36 |
Role-play.
Teach
FY1 about complaint procedures |
|
37 |
Role-play.
Topic
to be emailed just before the tutorial |
|
Blurb. Autosomal recessive condition |
|
|
39 |
SBA.
Quinolone
antibiotics |
36. Role-play.
Teach FY1 about complaint procedures.
A document about complaint procedures is attached to help you
prepare.
37. Role-play. Topic to
be emailed just before the tutorial.
38. Blurb. Autosomal recessive condition.
Discuss the essential components.
39. SBA. Quinolone antibiotics.
Quinolone &
fluoroquinolone antibacterial drugs
Abbreviations.
FQ: fluoroquinolone.
SLE: systemic lupus erythematosus.
QUI: quinolone.
Question 1. Which,
if any, of the following drugs are QUIs or FQs?
|
A |
cimetidine
|
|
B |
ciprofloxacin |
|
C |
nalidixic acid |
|
D |
neomycin |
|
E |
nitrofurantoin |
Question 2. Which,
if any, of the following statements are true in relation to QUIs & FQs?
|
A |
nalidixic
acid is an older quinolone and is mainly excreted in the urine |
|
B |
ciprofloxacin is effective against most Gram +ve and
–ve bacteria and 1st- line treatment for pneumococcal pneumonia. |
|
C |
ciprofloxacin is contraindicated in pregnancy due to
the ↑ risk of neonatal haemolysis |
|
D |
many staphylococci are resistant to quinolones |
|
E |
quinolones are particularly useful in the treatment of
MRSA |
Question 3. Which
was the first QUI antibiotic?
|
A |
acetylsalicylic
acid |
|
B |
nalidixic
acid |
|
C |
oxalic
acid |
|
D |
pipemidic
acid |
|
E |
none of
the above |
Question 4. How
do QUI and FQ antibiotics work?
|
A |
impair
bacterial DNA coiling |
|
B |
impair
bacterial DNA binding |
|
C |
impair
bacterial RNA action |
|
D |
impair
bacterial mitochondrial action |
|
E |
none of
the above. |
Question 5. Which,
if any, of the following QUIs & FQs is not available for prescription in
the UK.
|
A |
ciprofloxacin |
|
B |
levofloxacin |
|
C |
nalidixic
acid |
|
D |
moxifloxacin |
|
E |
ofloxacin |
Question 6. Which,
if any, of the following statements are true in relation to the quinolones and
fluoroquinolones
and pregnancy? This is not a true SBA as there may be more than one answer.
|
A |
FQs are
newer than QUIs with better systemic spread and efficacy |
|
B |
QUIs concentrate in urine but have a special affinity
for cartilage |
|
C |
consumption of a FQ in the 1st. trimester is
grounds for TOP |
|
D |
if an FQ is used, norfloxacin and ciprofloxacin should
be considered 1st. |
|
E |
FQs are linked to a risk of discolouration of the teeth
of offspring |
Question 7. Which
of the following is true about the warning issued by the FDA in 2008 in
relation
to QUIs
& FQs?
|
A |
they may
cause congenital cartilage defects |
|
B |
they may
cause congenital deafness |
|
C |
they may
cause tendonitis and tendon rupture |
|
D |
they may
cause prolongation of the Q-T interval |
|
E |
none of
the above |
Question 8. Which
of the following is true about the warning issued by the FDA in 2011 in
relation
to QUIs
& FQs?
|
A |
they may
cause exacerbation of eczema |
|
B |
they may
cause exacerbation of hypertension |
|
C |
they may
cause exacerbation of multiple sclerosis |
|
D |
they may
cause exacerbation of myasthenia gravis |
|
E |
they may
cause exacerbation of SLE |
Question 9. Which
of the following is true about the warning emphasised by the FDA in 2013 in
relation
to QUIs & FQs?
|
A |
they may
cause aortic dissection |
|
B |
they may
cause mitral stenosis |
|
C |
they may
cause pancreatitis |
|
D |
they may
cause peripheral neuropathy |
|
E |
they may
cause flare of SLE |
Question 10. FDA
issued a warning in July 2016. Which, if any, of the following were included?
|
A |
the
risks generally outweigh the benefits |
|
B |
QUIs
& FQs should not be used for acute
sinusitis, |
|
C |
QUIs
& FQs should not be used for exacerbation
of chronic bronchitis |
|
D |
QUIs
& FQs should not be used for uncomplicated
UTI |
|
E |
QUIs
& FQs may be useful for anthrax and plague |
Question 11. FDA
issued a warning in July 2018 about the use of FQs in pregnancy. Which, if any,
of
the
following were included in the reasons for its publication?
|
A |
to
strengthen previous warnings about hyperglycaemia and mental health risks |
|
B |
to
strengthen previous warnings about hypoglycaemia and mental health risks |
|
C |
to strengthen
previous warnings about the risk of ASD in the offspring |
|
D |
to
strengthen previous warnings about the risk of acute pancreatitis |
|
E |
to
strengthen previous warnings about the risk of PET |
Question 12. The
FDA issued a warning in December 2018 about the use of FQs in pregnancy.
Which, if
any, of the following was included? This is an SBA with only one correct
answer.
|
A |
↑ risk of atrial
fibrillation |
|
B |
↑ risk of aortic
aneurysm and rupture |
|
C |
↑ risk of
mitral stenosis |
|
D |
↑ risk of
pulmonary hypertension |
|
E |
↑ risk of
ulcerative colitis |
Question 13. What
appeared on the 3rd. page of the BMJ of the 24th.
February 2024 about fluoroquinolone drugs? This is an SBA with only one correct answer.
|
A |
a summary of MHRA’s advice of
January 2024 |
|
B |
a summary of the CDC’s advice
of January 2024 |
|
C |
warning that FQS and QUIS are
now banned |
|
D |
news flash re BIA President
requesting better advice |
|
E |
news flash re King Charles receiving
treatment with a FQ |
No comments:
Post a Comment